Contraceptive Special Issue

CRISPR/Cas9-based genome editing in mice uncovers 13 testis- or epididymis-enriched genes individually dispensable for male reproduction†

Jiang Sun1,2,+, Yonggang Lu1,+, Kaori Nozawa3,4, Zoulan Xu1,5, Akane Morohoshi1,2, Julio M. Castaneda1, Taichi Noda1, Haruhiko Miyata1, Ferheen Abbasi1,2, Hossam H. Shawk6, Satoru Takahashi7, Darius J. Devlin3,4, Zhifeng Yu3,4, Ryan M. Matzuk3,4, Thomas X. Garcia3,4,8, Martin M. Matzuk3,4,* and Masahito Ikawa1,2,5,9,*

1Department of Experimental Genome Research, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan, 2Graduate School of Medicine, Osaka University, Suita, Osaka, Japan, 3Center for Drug Discovery, Baylor College of Medicine, Houston, Texas, USA, 4Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA, 5Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan, 6Department of Comparative and Experimental Medicine, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan, 7Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, 8Department of Biology and Biotechnology, University of Houston-Clear Lake, Houston, Texas, USA and 9The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

*Correspondence: Department of Experimental Genome Research, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan. Tel: +81668798375; E-mail: ikawa@biken.osaka-u.ac.jp

†Grant Support: This research was supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT)/the Japan Society for the Promotion of Science (JSPS) (KAKENHI grants JP18K16735 to YL, JP19J12450 to AM, JP18K14715 to JMC, JP18K14612 and JP20H03172 to TN, JP17H04987 to HM, and JP17H01394 and JP19H05750 to MI); Japan Society for the Promotion of Science Overseas Research Fellowship and the Lalor Foundation (to KN); National Institute of General Medical Sciences (T32GM088129 and T32GM120011 to DJD); the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grants P01HD087157 and R01HD088412 to MMM and MI and R01HD095341 to TXG); the Bill and Melinda Gates Foundation (INV-001902 to MMM and MI); and the Japan Agency for Medical Research and Development (AMED) (grant JP19gm5010001 to MI).

‡These authors contributed equally to this work.

Received 14 February 2020; Revised 14 May 2020; Accepted 19 May 2020

Abstract

Developing a safe and effective male contraceptive remains a challenge in the field of medical science. Molecules that selectively target the male reproductive tract and whose targets are indispensable for male reproductive function serve among the best candidates for a novel non-hormonal male contraceptive method. To determine the function of these genes in vivo, mutant mice carrying disrupted testis- or epididymis-enriched genes were generated by zygote microinjection or electroporation of the CRISPR/Cas9 components. Male fecundity was determined by consecutively pairing knockout males with wild-type females and comparing the fecundity of...
Introduction

Contraceptive drugs have been available only for women for the past several decades, during which the world population underwent approximately a 2.4-fold increase, from 3 billion in 1960 to over 7.2 billion in 2015 [1]. The Strategic Plan 2000 of the National Institute of Child Health and Human Development states that uncontrolled fertility is one of the most pressing public health issues we face worldwide [2]. In the United States, approximately 49% of women have experienced an unintended pregnancy [3]. With such a high rate of unplanned pregnancies, there is an increased risk of adverse infant health outcomes, elevated rates of maternal mortality [4], ethical issues, social problems, and increased healthcare expenditure [5].

A lack of alternatives for contraception in men is partially responsible for these problems. However, the development of a safe and effective male contraceptive approach remains a long-term challenge in the field of medical science. So far, testosterone analogs have been the only approach in clinical trials that alter the production of endogenous androgens to produce a contraceptive effect in men [6]. To overcome the deficiency of contraceptive alternatives for men, non-hormonal male contraceptive pills can be developed to target the male reproductive tract in a reversible manner without jeopardizing normal hormone levels in men [7].

Due to extreme similarities between human and mouse genomes, the mouse has been serving as a powerful model organism for studying human diseases for decades [8]. Previous studies have demonstrated that more than 2300 genes are predominantly expressed in the male germ line, hundreds of which may be essential for male reproductive functions [9]. Nevertheless, only a limited number of testis- and epididymis-enriched genes have been documented regarding their roles in underpinning normal spermatogenesis and sperm functions such as glycosylphosphatidylinositol-anchored protein TEX101 [10], A kinase anchor protein AKAP4 [11], and sperm-specific glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase-5 [12], receptor tyrosine kinase, ROS proto-oncogene ROS1 [13], and epididymal receptor HER6 [14]. To further assess their potential as male contraceptive targets, the protein functions and interactions, spatiotemporal expression in male reproductive tract-enriched proteins cannot serve as targets for male contraceptive development because of their dispensable nature.

Materials and methods

Animals

Wild-type B6D2F1 and ICR mice used for experiments in the laboratory of MI were purchased from Japan SLC, Inc. or CLEA Japan, Inc. for knockout mouse production and phenotypic analyses. Wild-type mice obtained by intercrosses between C37BL6 and 129S5/SvEvBrd mice were used in the laboratories of MMM and TXG for analyzing the patterns of tissue expression for all candidate genes. All animal experiments were approved by the Animal Care and Use Committee of the Research Institute for Microbial Diseases, Osaka University and the Institutional Animal Care and Use Committee of Baylor College of Medicine.

Phylogenetic analyses

The phylogenetic trees of candidate genes were constructed by GENETYX software (GENETYX Corp., Tokyo, Japan) using the neighbor-joining method based on their amino acid sequences.

Digital PCR

Digital polymerase chain reaction (PCR) was conducted as previously described to depict the tissue expression of each candidate gene [15]. Sequences of various tissues were downloaded from Sequence Read Archive and aligned against the human genome (GRCh38) or mouse genome (GRCm38) by HISAT2 after being trimmed using TrimGalore. After quantification using featureCounts, the gene expression in each tissue was batch corrected by RUVR to remove the unwanted variation. Differential gene expression was further determined for each non-reproductive tissue against each reproductive tissue by EdgeR. The expression data for reproductive tissues were retrieved from 18 purified human germ cell data sets [22], 5 human testis data sets [23], 6 human epididymis segment data sets [24], whereas data for the 26 non-reproductive human tissues and the 14 non-reproductive mouse tissues were obtained from 118 and 62 additional data sets, respectively [25, 26].
In silico analyses of mRNA expression in spermatogenic cells

Messenger RNA (mRNA) expression of the genes of interest in testicular germ and somatic cells was examined in silico by 10x Genomics Loupe Browser using single-cell RNA-sequencing (scRNA-seq) data set published previously [27].

Mutant mouse production by CRISPR/Cas9

All mutant mice were generated by the CRISPR/Cas9 genome editing system. Single-guide RNAs (sgRNAs) were designed and off-target analyses were performed using the online software CRISPRDirect (crispr.dbcls.jp) [28]. The editing efficiency of each sgRNA was evaluated by the intensity of the fluorescence signal obtained from co-transfecting HEK293T cells with a pX459 plasmid (Addgene #62988) bearing the sgRNA sequence and a pCAG–EGfpFP plasmid (Addgene #50716) carrying the target sequence as described previously [29].

Wild-type fertilized eggs were collected from superovulated B6D2F1 female mice that had been paired with B6D2F1 males. To generate knockout mice via zygote electroporation, CRISPR RNA (crRNA)/trans-activating crRNA (tracrRNA)/Cas9 ribonucleoprotein complexes were introduced into two-pronuclear eggs using a NEPA21 super electroporator (NEPA GENE, Chiba, Japan) [30]. To generate mutant mice via zygote microinjection, pX459 plasmids encoding the sgRNAs and Cas9 protein were microinjected into the pronuclei of zygotes [29]. The treated zygotes were then cultured in potassium simplex optimization medium (KSOM) [31] to two-cell stage and transplanted into the oviducts of 0.5-day pseudopregnant ICR females. The founder generation was obtained by natural delivery or Cesarean section and genotyped by PCR and the mutant alleles were subsequently verified by Sanger sequencing.

The mutant mouse lines generated by zygote electroporation or microinjection are indicated in Supplementary Table S1. The primers and PCR conditions used for genotyping are enumerated in Supplementary Table S2.

Fertility tests for mutant males

Upon sexual maturity, homozygous or compound heterozygous mutant males were caged with three 8-week-old wild-type B6D2F1 females for at least 8 weeks. Exceptionally, Cabs1 homozygous mutant males were individually paired with two wild-type females for 8 weeks; Eddm3b and Lrcol1 mutant males were individually caged with one 8-week-old wild-type (in-house hybrid, C57BL/6J × 129S5/SvEvBrd) female for 16 weeks. For each mutant line, at least two males were tested for a valid statistical interpretation. Three B6D2F1 wild-type males were tested in parallel as positive controls. The number of pups was recorded at birth. The average litter size was calculated by dividing the total number of pups with the number of litters.

Analyses of testis weights and sperm motility

After the fertility tests, homozygous or compound heterozygous mutant male mice were anesthetized and euthanized by cervical dislocation. Testis weight relative to body weight was compared between wild-type and mutant males. The motility of cauda epididymal spermatozoa was analyzed using Hamilton Thorne CEROS II system (Hamilton Thorne Biosciences, Beverly, MA) at 10 min and 2 h of incubation in Toyoda, Yokoyama, Hoshi (TYH) medium.

Analyses of testis and epididymis histology and sperm morphology

Testes and epididymides were fixed in Bouin solution and embedded in paraffin wax. Paraffin sections were stained with periodic acid (Nacalai Tesque, Kyoto, Japan) and Schiff reagent (Wako, Osaka, Japan) and counterstained with Mayer hematoxylin solution (Wako, Osaka, Japan). The caudal epididymal spermatozoa were dispersed in TYH medium and observed under an Olympus BX53 phase contrast microscope.

Statistical analysis

Statistical analyses were carried out using the Student t-test. Differences were recognized as statistically significant when the P value was lower than 0.05.

Results

In silico expression and conservation analyses of candidate genes

Two major criteria for a human male contraceptive target are (i) male reproductive tract specificity to minimize potential side effects and (ii) the presence of a mouse ortholog for functional validation in an animal model. As disparities were found among different published databases, we further confirmed the expression patterns of the 13 genes of interest by digital PCR. As shown in Figure 1A, all genes exhibited predominant expression in the testes or epididymides of humans and mice. Using published scRNA-seq data generated from mouse and human spermatogenic cells at different stages, testis-enriched genes, 4921507P07Rik, Allc, Eddm3b, Lrcol1, Tmem114, and 4921507P07Rik were found to exhibit elevated mRNA expression in late spermatocytes or early spermatids in both mouse and human, whereas the mRNA expression of epididymis-enriched genes Eddm3b and Lrcol1 was below the level of detection in the male germ line of both species (Figure 1B). Notably, Tmem114, which showed a discrepancy of tissue expression bias in mouse and human (Figure 1A), was found to be expressed in the Sertoli cells in mouse but not expressed in the testis or somatic cells in human (Figure 1B).

Phylogenetic analyses indicated that all genes are conserved among mammals. 4921507P07Rik, Allc, Iqca, Tmem97, and Tmem114 were also found in zebrafish (Figure 2).

Phenotypic analyses of mutant males

To investigate if the candidate genes are essential for male reproduction, we disrupted the genes individually by the CRISPR/Cas9-mediated genome editing system. The mutant alleles were detected by genomic PCR and confirmed by Sanger sequencing. The mutated loci of all mouse lines were summarized in Supplementary Table S3. The Sanger sequencing result of 4921507P07Rik wild-type and homozygous knockout mice is shown as an example in Supplementary Figure S1. Herein, phenotypic analyses of Allc, Fscb, and 4921507P07Rik knockout mice are shown as examples for all genes.

Allc was deleted completely by introducing crRNA/tracrRNA/Cas9 complexes into two-pronuclear eggs via electroperoration. The two sgRNAs targeted the first coding exon (Exon 2) and the last coding exon (Exon 12; Figure 3A) of Allc. Off-target effect and cleavage efficiency of the two sgRNAs was evaluated using the CRISPRdirect software and EGfpFP reporter assay, respectively. Mutant allele carrying a 19 639-bp deletion was identified by genomic PCR and Sanger sequencing (Figure 3B and C) using the
Figure 1. In silico analyses of the expression patterns of specific genes in multiple tissues and spermatogenic cells. (A) Digital PCR indicates the expression patterns of several genes of interest in mouse and human tissues. The average transcript per million (TPM) value per tissue per gene was generated from 77 published mouse RNA-seq data sets and 147 human RNA-seq data sets, respectively. All 13 genes showed predominant or restricted expression in both mouse and human testes or epididymides. Black = maximum value TPM. (B) ScRNA-seq data depicting the median-normalized levels of mRNA expression of the 13 genes of interest during human and mouse spermatogenesis. Upper panel: The level of mRNA expression in each cell type is indicated by the band intensity. The threshold of median-normalized reads in mouse is set to nine, whereas the threshold in human is set to four. Lower panel: Linear graphs show the mRNA expression of each gene at various testicular germ and somatic cells. Ud Sg, undifferentiated spermatogonia; A1–A2 Sg, A1–A2 differentiating spermatogonia; A3–B Sg, A3–A4–In–B differentiating spermatogonia; D Sg, differentiated spermatogonia; Prele Sc, preleptotene spermatocytes; Le/Zy Sc, leptotene/zygotene spermatocytes; Pa Sc, pachytene spermatocytes; Di/Se Sc, diplotene/secondary spermatocytes; Early St, early round spermatids; Mid St, mid round spermatids; Late St, late round spermatids; SC, Sertoli cells; PTM, peritubular myoid cells; LC, Leydig cells; EC, endothelial cells; PC, perivascular cells.
Figure 2. Phylogenetic analysis of the 13 testis- or epididymis-enriched genes.

four primers presented in Figure 3A and Supplementary Table S2. No statistically significant difference was observed in the testis sizes and weights between the homozygous and heterozygous knockout mice (Figure 3D). Same as in the control samples, histological sections of knockout testes and epididymides showed normal spermatogenesis in the seminiferous tubules and normal sperm morphology and density in the caput and cauda epididymides (Figure 3E and Supplementary Figure S2). Moreover, the depletion of Allc did not affect the morphology of mature spermatozoa (Figure 3F). Computer-assisted sperm analysis revealed that Allc-null spermatozoa exhibited normal motility compared with control spermatozoa (Figure 3G).

Fscb is a gene containing a single coding exon. To disrupt this gene, two sgRNAs as indicated in Figure 4A were designed to target the 5' and 3' region, respectively, of the coding exon (Exon 1). Primers for identifying the mutant allele are presented in Figure 4A and B.
Figure 3. Phenotypic analysis of Allc knockout male mice. (A) Genomic structure and knockout strategy of Allc. Two sgRNAs were designed to target the first coding exon (Exon 2) and the last coding exon (Exon 12). Four primers (Fw1, Fw2, Rv1, and Rv2) were designed for genotyping the mutant mice. (B) Mutant and wild-type alleles were detected by genomic PCR using primer sets Fw1–Rv2 and Fw2–Rv1, respectively. (C) DNA sequence of the knockout allele was determined by Sanger sequencing. (D) Testis appearance and testis to body weight ratios of Allc heterozygous and homozygous knockout mice. Scale bar = 2 mm. (E) Histological analyses of testes and epididymides in Allc heterozygous and homozygous knockout mice. Scale bars = 50 μm. (F) Morphology of cauda epididymal spermatozoa in Allc heterozygous and homozygous knockout mice. Scale bars = 20 μm. (G) Analysis of sperm motility in Allc heterozygous and homozygous knockout mice. Sperm motility and kinetic parameters were measured at 10 and 120 min of incubation in TYH media. VAP, average path velocity; VSL, straight line velocity; VCL, curvilinear velocity; ALH, amplitude of lateral head displacement; BCF, beat cross frequency; STR, straightness; LIN, linearity.
Table 1. Outcomes of the fertility tests for the 13 mutant mouse lines. Compound heterozygotes carrying different mutations in each allele (−3166/−3164) were used for testing the fertility of Fscb knockout males. Exceptionally, Cabs1 mutant males were individually paired with two wild-type females and Eddm3b and Lrcoll mutant males were individually caged with one wild-type female.

| Gene symbol | Genotype | No. of males | No. of pups | No. of litters | Mating period | Average litter size |
|-------------|----------|--------------|-------------|----------------|---------------|-------------------|
| Wild-type   | +/+      | 3            | 264         | 30             | 10 weeks      | 8.8 ± 0.6         |
| 4921507P07Rik | −22195/−22195 | 3      | 185         | 19             | 8 weeks       | 9.7 ± 1.2         |
| Allc        | −19639/−19639 | 3      | 189         | 24             | 8 weeks       | 9.1 ± 1.4         |
| Cabs1       | −S/−S    | 3            | 121         | 13             | 8 weeks       | 9.3 ± 2.6         |
| Fam229b     | −3266 + 17−3266 + 17 | 3      | 233         | 23             | 8 weeks       | 10.1 ± 1.7        |
| Fscb        | −3166/−3164 | 3            | 192         | 20             | 8 weeks       | 9.6 ± 0.9         |
| Hdgfl1      | −1095/−1095 | 3            | 231         | 25             | 12 weeks      | 9.2 ± 2.3         |
| lqca        | −107633/−107633 | 2        | 139         | 16             | 8 weeks       | 8.7 ± 2.1         |
| Lelp1       | −577 + 118/−577 + 118 | 2        | 138         | 14             | 8 weeks       | 9.9 ± 1.9         |
| Spata24     | −5638/−5638 | 3            | 223         | 23             | 9 weeks       | 9.7 ± 0.7         |
| Tmem97      | −8286/−8286 | 3            | 255         | 26             | 12 weeks      | 8.5 ± 1.0         |
| Eddm3b      | −S/−S    | 4            | 133         | 15             | 16 weeks      | 9.0 ± 0.8         |
| Lrcoll      | −1196/−1196 | 5            | 187         | 20             | 16 weeks      | 9.5 ± 1.4         |
| Tmem1114    | −15261/−15261 | 3        | 251         | 28             | 12 weeks      | 9.0 ± 2.6         |

and Supplementary Table S2. Compound heterozygotes carrying a 3166 or 3164-bp deletion in each allele or homozygotes carrying a 3166-bp deletion in both alleles (Figure 4C) were used for analyzing the knockout phenotype. Fscb knockout mice exhibited normal testisicular size and weight (Figure 4D), normal testicular and epididymal histology and spermatogenesis (Figure 4E and Supplementary Figure S3), and normal sperm morphology and motility (Figure 4F and G).

Mutant mice carrying a 22 195-bp deletion in the locus of 4921507P07Rik were generated using two sgRNAs targeting Exons 2 and 10, respectively. Primers used to detect the mutant alleles are presented in Figure 5A and Supplementary Table S2. The testis size, weight and histology, spermatogenesis, and sperm morphology and motility were normal in homozygous knockout males (Figure 5 and Supplementary Figure S4).

Analyses of testis weights, testis and epididymis histology and sperm morphology in other mutant mouse lines were presented in Supplementary Table S4 and Supplementary Figures S5 and S6.

Fertility tests for mutant male mice

To examine the fecundity of knockout males, individual knockout male mice were caged with up to three wild-type female mice for at least 2 months. The fecundity of three wild-type males was tested in parallel as positive controls. The average litter size of each knockout male was approximately eight pups per litter, comparable to the wild-type controls as shown in Table 1. Thus, all of the mutant males in this study showed normal fertility.

Discussion

Contraceptives for females have been available for preventing unintended pregnancy for quite a long time, but many women do not use them because of potential side effects and inconvenience. In developing countries, more than 700 000 maternal deaths are related to unplanned pregnancies from 1995 to 2000 [6]. Developed countries also show high rates of unintended pregnancy—more than 50% women have experienced an unplanned pregnancy [32]. The lack of contraceptives for men is partially responsible for the high occurrence of unplanned pregnancies and the associated maternal mortality. At present, male contraceptives mainly consist of condoms and vasectomy. These methods are not ideal, because contraceptive failure may occasionally occur using condoms and vasectomy may neither assure successful reversal nor it is convenient. The only male contraceptive drugs in clinical trials are based on hormonal disruption [6], where the endogenous androgen production is inhibited, thereby impairing sperm production [33]. Although hormonal contraceptives appear to be safe, additional studies are required to investigate the long-term effects of testosterone administration for overall male health, because contraceptives would be used by healthy individuals for extended periods of time. Therefore, the development of non-hormonal male contraceptives is of immense importance.

When developing contraceptive drugs, one of the most important factors to be considered is target validation, which can be assessed by using knockout mice, antibodies, and known inhibitors. All of the 13 genes in this study have human orthologs and their amino acid sequences show high homology between mouse and human (Supplementary Figure S7), suggesting conserved gene function across species. An expression bias toward the male reproductive organ is another important criterion for a candidate contraceptive target. In this study, all candidate genes showed elevated expression in the testes or epididymides of human and mouse as shown in Figure 1A. Although some genes exhibited minor expression in other tissues, we did not observe any abnormal appearance or behavior in the mutant mice.

As presented in Supplementary Figures S8 and S9, indel mutations disrupted the functions of Cabs1 and Eddm3b by introducing premature stop codons. However, it is possible that the normal fecundity of the mutant males is attributed to the presence of functional truncated proteins produced by alternative splicing. To avoid such concerns, in the present study, all other 11 knockout mouse lines were generated by removing the entire open reading frames. To further enhance the screening stringency, all of the mutant mice were generated on a mixed background of B6D2F1/J mice. We deposited all of these mutant mouse lines to the bioresource center, which may be of value to other researchers for their studies (Supplementary Table S5).

By using the Mouse Genome Informatics database (informati cs.jax.org), UniProt (uniprot.org), NCBI’s Protein database (ncbi.
Figure 4. Phenotypic analysis of Fscb knockout male mice. (A) Genomic structure and knockout strategy of mouse Fscb. Two sgRNAs were designed to target the 5' and the 3' region, respectively, of the coding exon (Exon 1). Four primers (Fw1, Fw2, Rv1, and Rv2) were designed for genotyping. (B) Mutant and wild-type alleles were detected by genomic PCR using primer sets Fw1–Rv2 and Fw2–Rv1, respectively. (C) DNA sequence of the knockout allele was determined by Sanger sequencing. (D) Testis appearance and testis to body weight ratios of Fscb heterozygous and homozygous knockout mice. Scale bar = 2 mm. (E) Histological analyses of testes and epididymides in Fscb heterozygous and homozygous knockout mice. Scale bars = 50 μm. (F) Morphology of cauda epididymal spermatozoa in Fscb heterozygous and homozygous knockout mice. Scale bars = 20 μm. (G) Analysis of sperm motility in Fscb heterozygous and homozygous knockout mice. Sperm motility and kinetic parameters were measured at 10 and 120 min of incubation in TYH media.
Figure 5. Phenotypic analysis of 4921507P07Rik knockout male mice. (A) Genomic structure and knockout strategy of mouse 4921507P07Rik. Two sgRNAs were designed to target the first coding exon (Exon 2) and the 3' UTR region of the last coding exon (Exon 10). Three primers (Fw1, Rv1, and Rv2) were designed for genotyping. (B) Mutant and wild-type alleles were detected by genomic PCR using primer sets Fw1–Rv2 and Fw1–Rv1, respectively. (C) DNA sequence of the knockout allele was determined by Sanger sequencing. (D) Testis appearance and testis to body weight ratios of 4921507P07Rik heterozygous and homozygous knockout mice. Scale bar = 2 mm. (E) Histological analyses of testes and epididymides in 4921507P07Rik heterozygous and homozygous knockout mice. Scale bars = 50 μm. (F) Morphology of cauda epididymal spermatozoa in 4921507P07Rik heterozygous and homozygous knockout mice. Scale bars = 20 μm. (G) Analysis of sperm motility in 4921507P07Rik heterozygous and homozygous knockout mice. Sperm motility and kinetic parameters were measured at 10 and 120 min of incubation in TYH media.
levels and mating behaviors, or the well-being of their offspring. Bromodomain inhibitor JQ1 achieves a complete and reversible contraceptive effect without influencing the male mouse testosterone. The inhibition of BRDT using a small-molecule bromodomain (CABYR)-binding protein, FSCB, has been characterized as a sperm protein that is a direct target of protein kinase A (PKA)-mediated tyrosine phosphorylation during sperm capacitation. These studies suggested that FSCB may be essential for male reproduction. However, Fscb knockout males were found to have normal fecundity, suggesting that the depletion of Fscb does not affect sperm motility, capacitation, or the acrosome reaction.

In recent years, many of the testis-enriched genes essential for male reproduction were found by using the knockout approach. Some of them, such as bromodomain testis-specific protein (BRDT) and protein phosphatase 3 catalytic subunit gamma (PPP3CC), were recognized as candidate targets for non-hormonal male contraceptives. BRDT is a testis-specific bromodomain motif-containing protein and BRD7 knockout males are infertile due to abnormal spermatogenesis. The inhibition of BRDT using a small-molecule bromodomain inhibitor JQ1 achieves a complete and reversible contraceptive effect without influencing the male mouse testosteron levels and mating behaviors, or the well-being of their offspring.

Calcineurin is a Ca2+- and calmodulin-dependent serine-threonine phosphatase that is crucial for calcium signaling. PPP3CC has been identified as a catalytic subunit isoform of calcineurin in mammals. PPP3CC knockout mice showed normal spermatogenesis and sperm counts and morphology, yet displayed infertility due to defective zona pellucida penetration. Male mice exhibited defective sperm morphology and motility within 4 to 5 days after treatment of calcineurin inhibitors, such as cyclosporine A and FK506. The mice recovered from sterility after one week of stopping treatment, indicating that sperm calcineurin is a potential target for the development of reversible and rapid non-hormonal male contraceptives.

In conclusion, we disrupted 13 testis- or epididymis-enriched genes in mice by the CRISPR/Cas9 system. Fertility tests and phenotypic analyses of the mutant males revealed that all of these genes are dispensable for male fecundity in mice and are thus not suitable for further development as a male contraceptive target. Using this in vivo approach, essential genes that have novel functions in male reproduction can be efficiently identified. Our progress toward not only understanding the key molecules underpinning normal male reproduction, but also the identification of druggable targets for non-hormonal male contraceptives, has been vastly accelerated.

Acknowledgments
Authors thank Eri Hosoyamada and the Biotechnology Research and Development (nonprofit organization) for technical assistance. Authors are also grateful to Dr. Keisuke Shimada for assistance in sending mutant mice to Houston, Texas.

Conflict of interest
The authors have declared that no conflict of interest exists.

References
1. Castaneda J, Matzuk MM. Toward a rapid and reversible male pill. 2015; 350:385–386.
2. Finer LB, Zola MR. Declines in unintended pregnancy in the United States, 2008–2011. Science 2016; 374:843–832.
3. Finer LB, Zola MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478–485.
4. Gibson JD, Koeng MA, Hindin MJ. The effects of unintended pregnancy on infant child, and parental health: a review of the literature. Stud Fam Plann 2008; 39:18–38.
5. Sonfield A, Kost K. Public costs from unintended pregnancies and the role of public insurance programs in paying for pregnancy and infant care: estimates for 2008. Web Report. 2013.
6. Atzeni RJ, Baker MA, Doncel GF, Matzuk MM, Mauck CK, Harper MJ. As the world grows: contraception in the 21st century. J Clin Invest 2008; 118:1330–1343.
7. O’Rand MG, Silva EJ, Hamil KG. Non-hormonal male contraception: a review and development of an Eppin based contraceptive. Pharmacol Ther 2016; 157:105–111.
8. Archambault DR, Matzuk MM. Disrupting the male germ line to find infertility and contraception targets. Annu Rev Genet 2014; 58:101–108.
9. Schultz N, Hamra FK, Garbers DL. A multitude of genes expressed solely in meiotic or postmeiotic spermatogenic cells offers a myriad of contraceptive targets. Proc Natl Acad Sci U S A 2003; 100:12201–12206.
10. Fujihara Y, Tokuhira K, Muro Y, Kondoh G, Araki Y, Ikawa M, Okabe M. Expression of TEX101, regulated by ACE, is essential for the production of fertile mouse spermatozoa. Proc Natl Acad Sci U S A 2013; 110:8111–8116.
11. Miki K, Willis WD, Brown PR, Goulding EH, Fulcher KD, Eddy EM. Targeted disruption of the Akap4 gene causes defects in sperm flagellum and motility. Dev Biol 2002; 248:331–342.
12. Miki K, Qu W, Goulding EH, Willis WD, Bunch DO, Strader LF, Perreault SD, Eddy EM, O’Brien DA. Glyceraldehyde 3-phosphate
dehydrogenase-S, a sperm-specific glycolytic enzyme, is required for sperm motility and male fertility. *Proc Natl Acad Sci U S A* 2004; 101:16501–16506.

13. Yeung C-H, Wagenfeld A, Nieschlag E, Cooper TG. The cause of infertility. Genome editing reveals dispensable testis- and epididymis-enriched genes, 2020, Vol. 103, No. 2.

14. Davies B, Baumann C, Kirchhoff C, Ivell R, Nubbemeyer R, Habenicht U-.

15. Baker MA, Reeves G, Hetherington C, Baur I, Arken RJ. Identification of gene products present in Triton X-100 soluble and insoluble fractions of human spermatozoa lysates using LC-MS/MS analysis. *Proteomics Clin Appl* 2007; 1:524–532.

16. O’Rand MG, Romrell LJ. Appearance of cell surface auto- and isoanti-gens during spermogenesis in the rabbit. *Dev Biol* 1977; 55: 347–358.

17. Fujiyara N, Noda T, Kobayashi K, Oji A, Kobayashi S, Matsumura T, Larasati T, Oura S, Kojima-Kita K, Yu Z, Matzuk MM, Ikawa M. Identification of multiple male reproductive tract-specific proteins that regulate sperm migration through the oviduct in mice. *Proc Natl Acad Sci U S A* 2019; 116:18498–18506.

18. Holcomb RJ, Oura S, Nozawa K, Kent K, Yu Z, Robertson MJ, Coartá C, Matzuk MM, Ikawa M, Garcia TX. The testes-specific serine proteases PRSS44, PRSS46, and PRSS54 are dispensable for male mouse fertility. *Biol Reprod* 2020; 102:84–91.

19. Lu Y, Oura S, Matsumura T, Oji A, Sakurai N, Fujiyara Y, Shimada K, Miyata H, Tobita T, Noda T, Castaneda JM, Kiyozumi D et al. CRISPR/Cas9-mediated genome editing reveals 30 testes-enriched genes dispensable for male fertility in mice. *Biol Reprod* 2019; 101:501–511.

20. Miyata H, Castaneda JM, Fujiyara Y, Yu Z, Archambault DR, Isotani A, Kiyozumi D, Kriseman ML, Mashiko D, Matsumura T, Matzuk RM, Mori M et al. Genome engineering uncovers 54 evolutionarily conserved gens during spermatogenesis in the rabbit. *Mol Cell Proteomics* 2019; 18:601–611.

21. Noda T, Sakurai N, Nozawa K, Kobayashi S, Devlin DJ, Matzuk MM, Ikawa M. Nine genes abundantly expressed in the epididymis are not and single-cell RNA-Seq profiling reveal dynamic signaling and metabolic transitions during human spermatogonial stem cell development. *Cell Stem Cell* 2017; 21:533–546.e536.

22. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Montminy MR, Sivertsen B, Wilén M, Yu R, et al. The human proteome project. A comprehensive resource for investigating the functional diversity of the human proteome. *Nature* 2011; 471:178–183.

23. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Montminy MR, Sivertsen B, Wilén M, Yu R, et al. The human proteome project. A comprehensive resource for investigating the functional diversity of the human proteome. *Nature* 2011; 471:178–183.

24. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Montminy MR, Sivertsen B, Wilén M, Yu R, et al. The human proteome project. A comprehensive resource for investigating the functional diversity of the human proteome. *Nature* 2011; 471:178–183.

25. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Montminy MR, Sivertsen B, Wilén M, Yu R, et al. The human proteome project. A comprehensive resource for investigating the functional diversity of the human proteome. *Nature* 2011; 471:178–183.

26. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Montminy MR, Sivertsen B, Wilén M, Yu R, et al. The human proteome project. A comprehensive resource for investigating the functional diversity of the human proteome. *Nature* 2011; 471:178–183.

27. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Montminy MR, Sivertsen B, Wilén M, Yu R, et al. The human proteome project. A comprehensive resource for investigating the functional diversity of the human proteome. *Nature* 2011; 471:178–183.

28. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Montminy MR, Sivertsen B, Wilén M, Yu R, et al. The human proteome project. A comprehensive resource for investigating the functional diversity of the human proteome. *Nature* 2011; 471:178–183.

29. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Montminy MR, Sivertsen B, Wilén M, Yu R, et al. The human proteome project. A comprehensive resource for investigating the functional diversity of the human proteome. *Nature* 2011; 471:178–183.

30. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Montminy MR, Sivertsen B, Wilén M, Yu R, et al. The human proteome project. A comprehensive resource for investigating the functional diversity of the human proteome. *Nature* 2011; 471:178–183.
51. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, IJN F. Selective inhibition of BET bromodomains. *Nature* 2010; 468: 1067.

52. Matzuk Martin M, McKeown Michael R, Filippakopoulos P, Li Q, Ma L, Agno Julio E, Lemieux Madeleine E, Picaud S, Yu Richard N, Qi J, Knapp S, Bradner JE. Small-molecule inhibition of BRDT for male contraception. *Cell* 2012; 150:673–684.

53. Klee CB, Ren H, Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. *J Biol Chem* 1998; 273:13367–13370.

54. Rusnak F, Mertz P. Calcineurin: form and function. *Physiol Rev* 2000; 80:1483–1521.

55. Muramatsu T, Giri PR, Higuchi S, Kincaid RL. Molecular cloning of a calmodulin-dependent phosphatase from murine testis: identification of a developmentally expressed nonneural isoenzyme. *Proc Natl Acad Sci U S A* 1992; 89:529–533.

56. Miyata H, Satouh Y, Mashiko D, Muto M, Nozawa K, Shiba K, Fujihara Y, Isotani A, Inaba K, Ikawa M. Sperm calcineurin inhibition prevents mouse fertility with implications for male contraceptive. *Science* 2015; 350:442–445.

57. Hisatomi A, Fujihira S, Fujimoto Y, Fuji T, Mine Y, Ohara K. Effect of Prograf (FK506) on spermatogenesis in rats. *Toxicology* 1996; 109:75–83.

58. Seethalakshmi L, Menon M, Malhotra RK, Diamond DA. Effect of cyclosporine A on male reproduction in rats. *J Urol* 1987; 138:991–995.